Improvements can be expected by addressing key features of HER2-positive breast cancer linked to different sensitivity in term of hormone receptor status (positive versus negative), PIK3CA status (wild type versus mutant), and immune environment. This evidence concerns the gene ERBB2 and breast carcinoma.